

Winfried Häusser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4187732/publications.pdf>

Version: 2024-02-01

187
papers

14,328
citations

20759

60
h-index

23472

111
g-index

226
all docs

226
docs citations

226
times ranked

10666
citing authors

#	ARTICLE	IF	CITATIONS
1	Cautious Hope for Cannabidiol (<sc>CBD</sc>) in Rheumatology Care. Arthritis Care and Research, 2023, 75, 1371-1375.	1.5	22
2	Registerâ€based studies on cannabisâ€based medicines and medical cannabis need reliable diagnoses and cannabis treatment details. European Journal of Pain, 2022, 26, 3-4.	1.4	2
3	Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs, 2022, 36, 31-44.	2.7	34
4	Non-pharmacological interventions for fibromyalgia (fibromyalgia syndrome) in adults: an overview of Cochrane Reviews. The Cochrane Library, 2022, 2022, .	1.5	0
5	Cannabis-based medicines and medical cannabis for adults with cancer pain. The Cochrane Library, 2022, 2022, .	1.5	1
6	Spontaneously reported persistent symptoms related to coronavirus disease 2019 one year after hospital discharge. Schmerz, 2022, 36, 315-325.	2.7	6
7	Authors reply to the comment of BÃckryd et al.. European Journal of Pain, 2022, 26, 1176-1176.	1.4	0
8	Medicinal cannabis for chronic pain: The bermuda triangle of lowâ€quality studies, countless metaâ€analyses and conflicting recommendations. European Journal of Pain, 2022, 26, 1183-1185.	1.4	16
9	Longâ€term observational studies with cannabisâ€based medicines for chronic nonâ€cancer pain: A systematic review and metaâ€analysis of effectiveness and safety. European Journal of Pain, 2022, 26, 1221-1233.	1.4	23
10	Nociplastic pain is functional pain â€ Authors' reply. Lancet, The, 2022, 399, 1604.	6.3	1
11	Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Current Rheumatology Reports, 2022, 24, 238-246.	2.1	9
12	Is opioid therapy for chronic nonâ€cancer pain associated with a greater risk of allâ€cause mortality compared to nonâ€opioid analgesics? A systematic review of propensity score matched observational studies. European Journal of Pain, 2021, 25, 1195-1208.	1.4	10
13	European* clinical practice recommendations on opioids for chronic noncancer pain â€ Part 1: Role of opioids in the management of chronic noncancer pain. European Journal of Pain, 2021, 25, 949-968.	1.4	55
14	European clinical practice recommendations on opioids for chronic noncancer pain â€ Part 2: Special situations*. European Journal of Pain, 2021, 25, 969-985.	1.4	17
15	Longâ€term outcomes of children with severe chronic pain: Comparison of former patients with a community sample. European Journal of Pain, 2021, 25, 1329-1341.	1.4	8
16	Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet, The, 2021, 397, 2098-2110.	6.3	440
17	Is Europe also facing an opioid crisis?â€ A survey of European Pain Federation chapters. European Journal of Pain, 2021, 25, 1760-1769.	1.4	53
18	Pharmacological therapies for fibromyalgia (fibromyalgia syndrome) in adults - an overview of Cochrane Reviews. The Cochrane Library, 2021, 2021, .	1.5	2

#	ARTICLE	IF	CITATIONS
19	Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociceptive Pain. <i>Drugs</i> , 2021, 81, 2103-2116.	4.9	16
20	Fibromyalgia revisited: do latent class analyses of symptom profiles in the general population confirm 2016 fibromyalgia diagnostic criteria?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 128-136.	0.4	0
21	Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 115-119.	0.4	0
22	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 186-193.	0.4	1
23	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 120-127.	0.4	0
24	Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 115-119.	0.4	10
25	Fibromyalgia revisited: do latent class analyses of symptom profiles in the general population confirm 2016 fibromyalgia diagnostic criteria?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 128-136.	0.4	0
26	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 120-127.	0.4	4
27	Subjective Cognitive Dysfunction in Patients With and Without Fibromyalgia: Prevalence, Predictors, Correlates, and Consequences. <i>Cureus</i> , 2021, 13, e20351.	0.2	1
28	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.4	29
29	Cannabis-based medicines for chronic neuropathic pain in adults. <i>The Cochrane Library</i> , 2020, 2020, CD012182.	1.5	263
30	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. <i>The Cochrane Library</i> , 2020, 2020, CD010292.	1.5	58
31	Efficacy and harms of long-term opioid therapy in chronic non-cancer pain: Systematic review and meta-analysis of open-label extension trials with a study duration ≥ 26 weeks. <i>European Journal of Pain</i> , 2020, 24, 265-278.	1.4	55
32	Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. <i>European Journal of Pain</i> , 2020, 24, 3-18.	1.4	45
33	Opioids for chronic osteoarthritis pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. <i>European Journal of Pain</i> , 2020, 24, 685-703.	1.4	31
34	Opioids for chronic low back pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration. <i>European Journal of Pain</i> , 2020, 24, 497-517.	1.4	41
35	Evaluation of Quality of Life of Adult Patients with Celiac Disease in Argentina: From Questionnaire Validation to Assessment. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7051.	1.2	7
36	All-cause mortality in patients with long-term opioid therapy compared with non-opioid analgesics for chronic non-cancer pain: a database study. <i>BMC Medicine</i> , 2020, 18, 162.	2.3	24

#	ARTICLE	IF	CITATIONS
37	Considering the potential for an increase in chronic pain after the COVID-19 pandemic. <i>Pain</i> , 2020, 161, 1694-1697.	2.0	225
38	Long-term opioid therapy for chronic noncancer pain: second update of the German guidelines. <i>Pain Reports</i> , 2020, 5, e840.	1.4	16
39	Validation of the German version of the Bodily Distress Syndrome 25 checklist in a representative German population sample. <i>Journal of Psychosomatic Research</i> , 2020, 132, 109991.	1.2	18
40	Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada. <i>ACR Open Rheumatology</i> , 2020, 2, 286-293.	0.9	22
41	All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1457-1464.	1.6	9
42	Prevalence and overlap of somatic symptom disorder, bodily distress syndrome and fibromyalgia syndrome in the German general population: A cross sectional study. <i>Journal of Psychosomatic Research</i> , 2020, 133, 110111.	1.2	51
43	<i>Psychosomatik.</i> , 2020, , 517-524.		0
44	Primary and Secondary Fibromyalgia Are The Same: The Universality of Polysymptomatic Distress. <i>Journal of Rheumatology</i> , 2019, 46, 204-212.	1.0	34
45	Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. <i>Scandinavian Journal of Pain</i> , 2019, 20, 77-86.	0.5	50
46	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. <i>Autoimmunity Reviews</i> , 2019, 18, 102409.	2.5	26
47	Medical cannabis: strengthening evidence in the face of hype and public pressure. <i>Cmaj</i> , 2019, 191, E907-E908.	0.9	16
48	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2019, 46, 532-538.	1.0	38
49	Psychological therapies for chronic widespread pain and fibromyalgia syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101416.	1.4	12
50	Meta-analysis of Opioids for Chronic Pain. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1934.	3.8	2
51	Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. <i>Schmerz</i> , 2019, 33, 424-436.	2.7	72
52	Chronic primary pain: a pain-centered view of the world is too narrow. <i>Pain</i> , 2019, 160, 1683-1683.	2.0	10
53	Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora's box. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 258-271.	0.6	1
54	Fibromyalgia as a chronic primary pain syndrome: issues to discuss. <i>Pain</i> , 2019, 160, 2651-2652.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Obesity, depression and hip pain. <i>Musculoskeletal Care</i> , 2019, 17, 126-132.	0.6	19
56	The association of adverse childhood experiences and of resilience with chronic noncancer pain in the German adult population – A cross-sectional survey. <i>European Journal of Pain</i> , 2019, 23, 555-564.	1.4	8
57	Medical Cannabis for Older Patients. <i>Drugs and Aging</i> , 2019, 36, 39-51.	1.3	69
58	The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome: An Observational Study Using Routine Health Insurance Data. <i>Deutsches Ärzteblatt International</i> , 2019, 116, 463-470.	0.6	24
59	Schmerzmedizin bei Fibromyalgiesyndrom. <i>Springer Reference Medizin</i> , 2019, , 443-451.	0.0	0
60	Fibromyalgia syndrome: under-, over- and misdiagnosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 90-97.	0.4	25
61	Selective serotonin reuptake inhibitors for fibromyalgia syndrome. <i>The Cochrane Library</i> , 2018, 2018, CD011735.	1.5	52
62	Systematic review and meta-analysis of cannabinoids in palliative medicine. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 220-234.	2.9	106
63	Unravelling Fibromyalgia – Steps Toward Individualized Management. <i>Journal of Pain</i> , 2018, 19, 125-134.	0.7	50
64	Guideline-recommended vs high-dose long-term opioid therapy for chronic noncancer pain is associated with better health outcomes: data from a representative sample of the German population. <i>Pain</i> , 2018, 159, 85-91.	2.0	36
65	Mirtazapine for fibromyalgia in adults. <i>The Cochrane Library</i> , 2018, 8, CD012708.	1.5	19
66	Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1235-1254.	2.9	27
67	Fibromyalgia diagnosis and biased assessment: Sex, prevalence and bias. <i>PLoS ONE</i> , 2018, 13, e0203755.	1.1	194
68	Quality of Life of Celiac Patients in Brazil: Questionnaire Translation, Cultural Adaptation and Validation. <i>Nutrients</i> , 2018, 10, 1167.	1.7	35
69	Systematic reviews with meta-analysis on cannabis-based medicines for chronic pain: a methodological and political minefield. <i>Pain</i> , 2018, 159, 1906-1907.	2.0	32
70	European Pain Federation (<sc>EFIC</sc>) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. <i>European Journal of Pain</i> , 2018, 22, 1547-1564.	1.4	149
71	Facts and myths pertaining to fibromyalgia. <i>Dialogues in Clinical Neuroscience</i> , 2018, 20, 53-62.	1.8	123
72	The Perils of Overestimating the Efficacy of Cannabis-Based Medicines for Chronic Pain Management. <i>Pain Physician</i> , 2018, 1, E79-E85.	0.3	8

#	ARTICLE	IF	CITATIONS
73	Schmerzmedizin bei Fibromyalgiesyndrom. , 2018, , 1-9.		0
74	Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in American and Israeli rheumatoid arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 575-580.	0.4	1
75	Cognitive behavioural therapies for fibromyalgia. <i>The Cochrane Library</i> , 2017, 2017, CD009796.	1.5	125
76	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e54-e54.	0.5	33
77	The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. <i>Pain Reports</i> , 2017, 2, e599.	1.4	119
78	Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. <i>The Cochrane Library</i> , 2017, 3, CD012332.	1.5	27
79	Anticonvulsants for fibromyalgia. <i>The Cochrane Library</i> , 2017, 2017, CD010782.	1.5	32
80	Treatâ€œTarget Strategy for Fibromyalgia: Opening the Dialogue. <i>Arthritis Care and Research</i> , 2017, 69, 462-466.	1.5	13
81	Cannabinoids in Pain Management and Palliative Medicine. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 627-634.	0.6	66
82	Self-Reported Childhood Maltreatment and Traumatic Events among Israeli Patients Suffering from Fibromyalgia and Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2017, 2017, 1-8.	0.7	26
83	A paradigm change to inform fibromyalgia research priorities by engaging patients and health care professionals. <i>Canadian Journal of Pain</i> , 2017, 1, 137-147.	0.6	19
84	The Efficacy, Safety and Applications of Medical Hypnosis: A Systematic Review of Meta-analyses. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 289-96.	0.6	59
85	Patterns of Childhood Abuse and Neglect in a Representative German Population Sample. <i>PLoS ONE</i> , 2016, 11, e0159510.	1.1	32
86	Comparison of Physicianâ€œBased and Patientâ€œBased Criteria for the Diagnosis of Fibromyalgia. <i>Arthritis Care and Research</i> , 2016, 68, 652-659.	1.5	29
87	The Polysymptomatic Distress Scale Is Simple, Useful, and Effective in Clinical Care and Clinical and Epidemiology Studies. <i>Journal of Rheumatology</i> , 2016, 43, 454-454.	1.0	7
88	Antipsychotics for fibromyalgia in adults. <i>The Cochrane Library</i> , 2016, 2016, CD011804.	1.5	25
89	Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. <i>Arthritis Care and Research</i> , 2016, 68, 681-688.	1.5	60
90	Family physicianâ€œpatient relationship and frequent attendance of primary and specialist health care: Results from a German population-based cohort study. <i>Patient Education and Counseling</i> , 2016, 99, 1213-1219.	1.0	22

#	ARTICLE	IF	CITATIONS
91	Widespread Pain and Low Widespread Pain Index Scores among Fibromyalgia-positive Cases Assessed with the 2010/2011 Fibromyalgia Criteria. <i>Journal of Rheumatology</i> , 2016, 43, 1743-1748.	1.0	39
92	2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 319-329.	1.6	1,173
93	Cannabinoids for fibromyalgia. <i>The Cochrane Library</i> , 2016, 7, CD011694.	1.5	56
94	PTSD and Fibromyalgia Syndrome: Focus on Prevalence, Mechanisms, and Impact. , 2016, , 563-577.		2
95	Fibromyalgia syndrome: novel therapeutic targets. <i>Pain Management</i> , 2016, 6, 371-381.	0.7	14
96	Prevalence of self-reported jaw pain in Germany: two cross-sectional surveys of the general German population. <i>Clinical Oral Investigations</i> , 2016, 20, 1895-1901.	1.4	10
97	Fibromyalgia. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15022.	18.1	308
98	Prevalence of Chronic Disabling Noncancer Pain and Associated Demographic and Medical Variables. <i>Clinical Journal of Pain</i> , 2015, 31, 886-892.	0.8	48
99	A Systematic Overview of Reviews for Complementary and Alternative Therapies in the Treatment of the Fibromyalgia Syndrome. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-13.	0.5	65
100	Meta-analyses of pain studies: What we have learned. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 131-146.	1.4	10
101	Construct validity and clinical utility of current research criteria of DSM-5 somatic symptom disorder diagnosis in patients with fibromyalgia syndrome. <i>Journal of Psychosomatic Research</i> , 2015, 78, 546-552.	1.2	43
102	Validation of the Turkish version of the Celiac Disease Questionnaire (CDQ). <i>Health and Quality of Life Outcomes</i> , 2015, 13, 82.	1.0	19
103	The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity. <i>Journal of Rheumatology</i> , 2015, 42, 1494-1501.	1.0	70
104	PTSD and Fibromyalgia Syndrome: Focus on Prevalence, Mechanisms, and Impact. , 2015, , 1-13.		2
105	Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in fibromyalgia syndrome: a comparison of US and German outpatients. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S86-92.	0.4	18
106	Opioid therapy in the treatment of chronic pain conditions in Germany. <i>Pain Physician</i> , 2015, 18, E323-31.	0.3	22
107	Symptoms, the Nature of Fibromyalgia, and Diagnostic and Statistical Manual 5 (DSM-5) Defined Mental Illness in Patients with Rheumatoid Arthritis and Fibromyalgia. <i>PLoS ONE</i> , 2014, 9, e88740.	1.1	59
108	Complementary and Alternative Medicine for the Treatment of Fibromyalgia. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-2.	0.5	9

#	ARTICLE	IF	CITATIONS
109	Long-Term Opioid Use in Non-Cancer Pain. Deutsches Ärzteblatt International, 2014, 111, 732-40.	0.6	85
110	Social Security Work Disability and Its Predictors in Patients With Fibromyalgia. Arthritis Care and Research, 2014, 66, 1354-1363.	1.5	27
111	Patient Health Questionnaire 15 as a generic measure of severity in fibromyalgia syndrome: Surveys with patients of three different settings. Journal of Psychosomatic Research, 2014, 76, 307-311.	1.2	30
112	Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research and Therapy, 2014, 16, 201.	1.6	126
113	Fibromyalgia and Physical Trauma: The Concepts We Invent. Journal of Rheumatology, 2014, 41, 1737-1745.	1.0	25
114	Untying chronic pain: prevalence and societal burden of chronic pain stages in the general population - a cross-sectional survey. BMC Public Health, 2014, 14, 352.	1.2	88
115	The Impact of Body Weight and Depression on Low Back Pain in a Representative Population Sample. Pain Medicine, 2014, 15, 1316-1327.	0.9	23
116	Validation of the Patient-Doctor-Relationship Questionnaire (PDRQ-9) in a Representative Cross-Sectional German Population Survey. PLoS ONE, 2014, 9, e91964.	1.1	34
117	Schmerzmedizin bei Fibromyalgiesyndrom. , 2014, , 1-12.		0
118	Posttraumatic stress disorder in fibromyalgia syndrome: Prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain, 2013, 154, 1216-1223.	2.0	132
119	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	0.6	422
120	Frequency of child maltreatment in a representative sample of the German population. BMC Public Health, 2013, 13, 980.	1.2	82
121	The Association Among Childhood Maltreatment, Somatic Symptom Intensity, Depression, and Somatoform Dissociative Symptoms in Patients with Fibromyalgia Syndrome: A Single-Center Cohort Study. Journal of Trauma and Dissociation, 2013, 14, 342-358.	1.0	35
122	Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Annals of the Rheumatic Diseases, 2013, 72, 955-962.	0.5	190
123	The somatic symptom disorder in DSM 5 risks mislabelling people with major medical diseases as mentally ill. Journal of Psychosomatic Research, 2013, 75, 586-587.	1.2	22
124	Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials. Rheumatology International, 2013, 33, 193-207.	1.5	124
125	Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane Library, 2013, , CD010292.	1.5	96
126	Fibromyalgia Prevalence, Somatic Symptom Reporting, and the Dimensionality of Polysymptomatic Distress: Results From a Survey of the General Population. Arthritis Care and Research, 2013, 65, 777-785.	1.5	352

#	ARTICLE	IF	CITATIONS
127	Anticonvulsants for fibromyalgia. , 2013, , CD010782.		54
128	Spa Treatment (Balneotherapy) for Fibromyalgia—A Qualitative-Narrative Review and a Historical Perspective. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-5.	0.5	29
129	Classification and Clinical Diagnosis of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-9.	0.5	49
130	Treatment of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines with Special Emphasis on Complementary and Alternative Therapies. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-7.	0.5	108
131	A Systematic Review and Meta-Analysis of Qigong for the Fibromyalgia Syndrome. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-12.	0.5	35
132	Efficacy of EMG- and EEG-Biofeedback in Fibromyalgia Syndrome: A Meta-Analysis and a Systematic Review of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-11.	0.5	65
133	Short-Term Stress, but Not Mucosal Healing Nor Depression Was Predictive for the Risk of Relapse in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 2380-2386.	0.9	71
134	Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy. Clinical Journal of Pain, 2012, 28, 437-451.	0.8	73
135	The Role of Antidepressants in the Management of Fibromyalgia Syndrome. CNS Drugs, 2012, 26, 297-307.	2.7	140
136	The German fibromyalgia consumer reports — a cross-sectional survey. BMC Musculoskeletal Disorders, 2012, 13, 74.	0.8	60
137	Widespread pain in older Germans is associated with posttraumatic stress disorder and lifetime employment status — Results of a cross-sectional survey with a representative population sample. Pain, 2012, 153, 2466-2472.	2.0	24
138	Validation of the Fibromyalgia Survey Questionnaire within a Cross-Sectional Survey. PLoS ONE, 2012, 7, e37504.	1.1	112
139	Nocebo Phenomena in Medicine. Deutsches Ärztblatt International, 2012, 109, 459-65.	0.6	183
140	Functional Bowel Disorders in Adults. Deutsches Ärztblatt International, 2012, 109, 83-94.	0.6	31
141	Non-Specific, Functional, and Somatoform Bodily Complaints. Deutsches Ärztblatt International, 2012, 109, 803-13.	0.6	133
142	Is the association of self-reported childhood maltreatments and adult fibromyalgia syndrome attributable to depression? A case control study. Clinical and Experimental Rheumatology, 2012, 30, 59-64.	0.4	15
143	Hearing loss in fibromyalgia? Somatic sensory and non-sensory symptoms in patients with fibromyalgia and other rheumatic disorders. Clinical and Experimental Rheumatology, 2012, 30, 88-93.	0.4	13
144	Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clinical and Experimental Rheumatology, 2012, 30, 78-87.	0.4	51

#	ARTICLE	IF	CITATIONS
145	Depression and mucosal proinflammatory cytokines are associated in patients with ulcerative colitis and pouchitis – A pilot study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 350-353.	0.6	18
146	Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 245.	0.8	204
147	Fibromyalgia diagnosis and diagnostic criteria. <i>Annals of Medicine</i> , 2011, 43, 495-502.	1.5	117
148	A comparison of the clinical features of fibromyalgia syndrome in different settings. <i>European Journal of Pain</i> , 2011, 15, 936-941.	1.4	11
149	Maltreatment in Childhood and Adolescence. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 287-94.	0.6	204
150	Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy – magnitude and patient-related predictors. <i>Pain</i> , 2011, 152, 1709-1717.	2.0	101
151	Demographic and Clinical Features of Patients With Fibromyalgia Syndrome of Different Settings: A Gender Comparison. <i>Gender Medicine</i> , 2011, 8, 116-125.	1.4	36
152	Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. <i>Arthritis Care and Research</i> , 2011, 63, 808-820.	1.5	181
153	Anxiety and depression in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 621-632.	0.9	129
154	Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. <i>Journal of Rheumatology</i> , 2011, 38, 1113-1122.	1.0	1,162
155	Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. <i>Rheumatology</i> , 2011, 50, 532-543.	0.9	264
156	The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients. <i>Journal of Rheumatology</i> , 2011, 38, 2238-2246.	1.0	130
157	Fibromyalgiesyndrom. , 2011, , 403-410.		1
158	Diagnosis of Fibromyalgia Syndrome – A Comparison of Association of the Medical Scientific Societies in Germany, Survey, and American College of Rheumatology Criteria. <i>Clinical Journal of Pain</i> , 2010, 26, 505-511.	0.8	38
159	Guidelines on the management of fibromyalgia syndrome – A systematic review. <i>European Journal of Pain</i> , 2010, 14, 5-10.	1.4	274
160	Anxiety and depression in adult patients with celiac disease on a gluten-free diet. <i>World Journal of Gastroenterology</i> , 2010, 16, 2780.	1.4	78
161	Efficacy of acupuncture in fibromyalgia syndrome – a systematic review with a meta-analysis of controlled clinical trials. <i>Rheumatology</i> , 2010, 49, 778-788.	0.9	102
162	Fibromyalgiesyndrom (FMS). <i>DoctorConsult - the Journal Wissen Fur Klinik Und Praxis</i> , 2010, 1, e93-e98.	0.0	0

#	ARTICLE	IF	CITATIONS
163	Efficacy of Cognitive-Behavioral Therapies in Fibromyalgia Syndrome – A Systematic Review and Metaanalysis of Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2010, 37, 1991-2005.	1.0	218
164	Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome. <i>Journal of Pain</i> , 2010, 11, 505-521.	0.7	154
165	Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. <i>Arthritis Research and Therapy</i> , 2010, 12, R79.	1.6	317
166	Fibromyalgia Syndrome. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 383-91.	0.6	73
167	A Cluster Within the Continuum of Biopsychosocial Distress Can Be Labeled ‘Fibromyalgia Syndrome’ – Evidence from a Representative German Population Survey. <i>Journal of Rheumatology</i> , 2009, 36, 2806-2812.	1.0	61
168	Treatment of Fibromyalgia Syndrome With Antidepressants. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 198.	3.8	284
169	Treatment of fibromyalgia syndrome with gabapentin and pregabalin – A meta-analysis of randomized controlled trials. <i>Pain</i> , 2009, 145, 69-81.	2.0	195
170	Efficacy of multicomponent treatment in fibromyalgia syndrome: A meta-analysis of randomized controlled clinical trials. <i>Arthritis and Rheumatism</i> , 2009, 61, 216-224.	6.7	291
171	Efficacy of hydrotherapy in fibromyalgia syndrome – a meta-analysis of randomized controlled clinical trials. <i>Rheumatology</i> , 2009, 48, 1155-1159.	0.9	97
172	A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. <i>Arthritis and Rheumatism</i> , 2008, 59, 1279-1298.	6.7	105
173	Management of fibromyalgia syndrome – an interdisciplinary evidence-based guideline. <i>GMS German Medical Science</i> , 2008, 6, Doc14.	2.7	21
174	Development and Validation of the Celiac Disease Questionnaire (CDQ), a Disease-specific Health-related Quality of Life Measure for Adult Patients With Celiac Disease. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 157-166.	1.1	79
175	Predictors of Irritable Bowel-Type Symptoms and Healthcare-Seeking Behavior Among Adults With Celiac Disease. <i>Psychosomatic Medicine</i> , 2007, 69, 370-376.	1.3	24
176	Psychosomatische Aspekte chronischer Lebererkrankungen. , 2007, , 183-206.		0
177	Health-related quality of life in adult coeliac disease in Germany: results of a national survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 747-754.	0.8	89
178	Mental Disorder and Psychologic Distress in Patients With Ulcerative Colitis After Ileal Pouch-Anal Anastomosis. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 952-962.	0.7	7
179	Biopsychosocial Determinants of Health-Related Quality of Life After Ileal Pouch Anal Anastomosis for Ulcerative Colitis*. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 399-407.	0.9	29
180	Determinants of health-related quality of life in patients with chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 157-163.	2.4	95

#	ARTICLE	IF	CITATIONS
181	Biopsychosocial Predictors of Health-Related Quality of Life in Patients With Chronic Hepatitis C. Psychosomatic Medicine, 2004, 66, 954-958.	1.3	73
182	Validation of the German version of the Chronic Liver Disease Questionnaire. European Journal of Gastroenterology and Hepatology, 2004, 16, 599-606.	0.8	55
183	Internal psychosomatic medicine within the German Diagnosis Related Groups System. Gms Psycho-social-medicine, 2004, 1, Doc02.	1.2	2
184	Mirtazapine for fibromyalgia in adults. The Cochrane Library, 0, , .	1.5	8
185	Pharmacological therapies for fibromyalgia in adults - an overview of Cochrane Reviews. The Cochrane Library, 0, , .	1.5	5
186	Fibromyalgia Syndromeâ€”Classification, Diagnosis, and Treatment: In reply. Deutsches Ärztblatt International, 0, , .	0.6	2
187	Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11: the potential for negative consequences for patient care and research. Clinical and Experimental Rheumatology, 0, , .	0.4	0